大眾公用(01635.HK):民樸厚德基金總計認繳出資額11.02億元
格隆匯 2 月 8日丨大眾公用(01635.HK)公佈,2020年8月19日,公司受讓上海商言投資中心(有限合夥)在民樸厚德基金尚未出資的人民幣5億元認繳出資份額,成為民樸厚德基金新的有限合夥人,佔募集總規模的45.37%。2020年9月14日,公司將參股的民樸厚德基金中尚未出資份額中的1.5億元的認繳出資份額轉讓給大眾交通。
根據民樸厚德基金2020年第一次合夥人大會決議,截止公吿披露日,民樸厚德基金總計認繳出資額11.02億元人民幣,全體合夥人實繳出資金額為人民幣5.7576億元,民樸厚德基金後續不再要求各合夥人向基金進行出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.